Emily Menendez

GU Oncology Now

Phase 2 of SOLAR, a clinical trial designed by Curium Pharma, <a href="https://www.globenewswire.com/news-release/2023/08/15/2725665/0/en/Curium-Announces-Achievement-of-Co-Primary-Endpoints-in-Phase-2-of-Its-Phase-1-2-SOLAR-Clinical-Trial-Imaging-Men-With-Histologically-Proven-Prostate-Cancer-Using-Copper-Cu-64-PSMA.html" target="_blank" rel="noopener">achieved its co-primary end points of region-level correct localization rate and patient-level correct detection rate</a> for the use of Copper Cu 64 prostate-specific membrane antigen (PSMA) I&amp;T injections in patients with histologically proven metastatic prostate cancer.The SOLAR trial aimed to evaluate the safety, biodistribution, and image quality of Copper Cu 64 PSMA I&amp;T to detect metastatic prostate cancer using positron emission tomography/computed tomography (PET/CT) imaging. A total of 26 patients with metastatic prostate cancer were administered Copper Cu 64 PSMA I&amp;T injections in 7- to 9-mCi intravenous doses. PET/CT images were taken for each patient at 1 hour &plusmn; 15 minutes and 4 hours &plusmn; 30 minutes after administration.&ldquo;We are very pleased to report that our Copper Cu 64 PSMA I&amp;T product for PET/CT imaging in the detection of recurrent prostate cancer has met the co-primary end points,&rdquo; said Sakir Mutevelic, MD, MSc, chief medical officer at Curium, in a press release. &ldquo;Consistent with our mission to redefine the experience of cancer through our trusted legacy in nuclear medicine, we are encouraged by the readouts of the SOLAR phase 2 clinical trial. Our goal is to accelerate the Copper Cu 64 PSMA I&amp;T phase 3 clinical development and move forward with pivotal phase 3 clinical trials in biochemical recurrence and initial staging setting in metastatic prostate cancer in early 2024.&rdquo;

Copper Cu 64 PSMA I&T Demonstrates Correct Localization, Detection Rates in Prostate Cancer

Prostate Cancer Diagnostics

The SOLAR trial aimed to evaluate the safety, biodistribution, and image quality of Copper Cu 64 PSMA I&T to detect prostate cancer using PET/CT imaging.

Copper Cu 64 PSMA I&T Demonstrates Correct Localization for PCa

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe